The CLIMB Study
This program is supported by Novartis Pharmaceuticals Corporation. Content is independently developed by CMSC.
Tanuja Chitnis, MD, discusses the CLIMB database and study to identify predictors of future disease and determine the effect of treatment on progressions and disability.
EP: 1.The Value of Biomarker in Multiple Sclerosis
EP: 2.Evolving Methods of Multiple Sclerosis Diagnosis
EP: 3.Assays to Detect Neurofilament Light
EP: 4.Challenges and Opportunity With MRI
EP: 5.Neurofilament Light Chain and Acute Gadolinium Enhancing Lesions
EP: 6.Exploring Potential Applications of Neurofilament Light Chain in MS Prognosis and Care
EP: 7.Practical Considerations for the Use of Neurofilament Light Chain and MRI
EP: 8.How to Address Increasing Neurofilament Light Chain Levels
EP: 9.Weighing Treatment Decisions Based on Neurofilament Light Chain Levels
EP: 10.Monitoring Patients After a Change in Treatment Regimen
EP: 11.Assessing Lesion Types With MS Biomarkers
EP: 12.Neurofilament Light Chain and MS Prognosis, Treatment Effect, and Anticipation of Disease
EP: 13.The CLIMB Study
EP: 14.Reimbursement for MRI
EP: 15.Understanding the Underlying Progression of Multiple Sclerosis
EP: 16.Biomarkers, Patient Communication, and the Future of Care
EP: 17.Question and Answer about Neurofilament Light Chain and Other MS Biomarkers
Tanuja Chitnis, MD, discusses findings from the CLIMB study, a longitudinal natural history study focused on monitoring over 2,000 MS patients. Key insights include the correlation between early neurofilament light chain (NFL) levels and long-term prognosis, such as brain atrophy, thalamic atrophy, and the number of lesions at 10 years. Additionally, the study explores the inflammatory nature of MS in younger patients, as reflected in higher NFL levels during attacks.
Tanuja Chitnis, MD, mentions a novel aspect of the CLIMB study related to treatment discontinuation. Patients who decided to stop treatment were monitored for changes in NFL levels, with an increase predicting future disease activity and disability.
The discussion shifts to the need for studying for NFL as a biomarker. Experts emphasize the importance of investigating whether NFL changes precede other indicators like MRI or clinical activity, proposing a large-scale study to establish the predictability of NFL in relation to other markers.
Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.
